The team suggests using new drugs called mTOR inhibitors to treat these rare conditions. Dr. Matteo Barberis, lead author of the study and Reader in Systems Biology from the University of Surrey ...

DelveInsight's "FYARRO Market Size, Forecast, and Market Insight Report" highlights the details around FYARRO, an mTOR ...

AKT inhibitor Truqap (capivasertib) has been cleared by NICE for use in combination with standard therapy fulvestrant for ...

Rapamycin (Sirolimus, Rapamune) and its derivatives are mTOR inhibitors. Background on rapamycin Rapamycin is an immunosuppressant indicated for prophylaxis against organ rejection in kidney ...

Because of the near-simultaneous approval of new metastatic RCC therapies that act on VEGF and the HIF transcription cascade, Trx inhibitors such as MGd should be explored as potential candidates ...

Although recommended, many patients with metastatic clear cell RCC still don’t receive immune checkpoint inhibitor-based combinations as first-line treatment.

FYARRO holds strong market potential, particularly in treating rare and aggressive cancers like PEComa, where treatment options are limited. As the first FDA-approved therapy for advanced PEComa ...